US2019314510A1PendingUtilityA1

Methods and compositions for the sustained release of chromium

67
Assignee: JDS THERAPEUTICS LLCPriority: Mar 13, 2007Filed: Mar 20, 2019Published: Oct 17, 2019
Est. expiryMar 13, 2027(~0.6 yrs left)· nominal 20-yr term from priority
Inventors:James R. Komorowski
A61P 3/06A61P 3/08A61P 5/50A61P 9/00A61P 3/10A61P 3/00A23V 2002/00A61K 31/445A61K 47/547A23L 33/165A61K 31/4402A61K 47/545A61K 31/00A61K 31/4172A61K 31/28A61K 33/24
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition comprising:
 a chromium complex comprising:
 an amount of a fast-acting chromium complex; and 
 an amount of a slow-acting chromium complex; 
 wherein the amount of a fast acting chromium complex and the amount of the slow-reacting chromium complex are formulated to have a molar ratio of chromium between 1:10 and 10:1. 
   
     
     
         2 . The composition of  claim 1 , wherein the chromium complex is a hydrophobic chromium complex. 
     
     
         3 . The composition of  claim 1 , wherein the fast-acting chromium complex is hydrophilic and the slow-acting chromium complex is lipophilic. 
     
     
         4 . The composition of  claim 1 , wherein the slow-acting chromium complex is lipophilic. 
     
     
         5 . The composition of  claim 1 , wherein the fast-acting chromium complex is hydrophilic. 
     
     
         6 . The composition of  claim 1 , wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:8 and 8:1. 
     
     
         7 . The composition of  claim 1 , wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:4 and 4:1. 
     
     
         8 . The composition of  claim 1 , wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:2 and 2:1. 
     
     
         9 . The composition of  claim 1 , wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium of about 1:1. 
     
     
         10 . The composition of  claim 1 , wherein the amount of a fast-acting chromium complex comprises a chromium histidinate complex. 
     
     
         11 . The composition of  claim 1 , wherein the amount of a fast-acting chromium complex consists essentially of a chromium histidinate complex. 
     
     
         12 . The composition of  claim 1 , wherein the amount of a fast-acting chromium complex comprises, chromium acetate, chromium chloride, chromium histidinate, and chromium nicotinate, or any combination thereof. 
     
     
         13 . The composition of  claim 1 , wherein the first amount of a fast-acting chromium complex comprises chromium histidinate, chromium trihistidinate, chromium polyhistidinate, or any combination thereof. 
     
     
         14 . The composition of  claim 1 , further comprising metformin. 
     
     
         15 . The composition of  claim 1 , further comprising a pharmaceutically acceptable vehicle. 
     
     
         16 . The composition of  claim 1 , wherein the slow-acting chromium complex comprises chromium picolinate, chromium tripicolinate, or a combination thereof. 
     
     
         17 . The composition of  claim 1 , wherein the slow-acting chromium complex comprises chromium picolinate. 
     
     
         18 . The composition of  claim 1 , wherein the slow-acting chromium complex comprises chromium tripicolinate. 
     
     
         19 . The composition of  claim 1 , wherein the slow-acting chromium complex provides a glucose lowering effect. 
     
     
         20 . The composition of  claim 1 , wherein the slow-acting chromium complex provides a glucose stabilization effect for at least 10 hours.

Join the waitlist — get patent alerts

Track US2019314510A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.